Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genfit SA

www.genfit.com

Latest From Genfit SA

Intercept’s NASH Approval Timeline Shuffled Again With FDA Delay

The company said a planned 9 June advisory committee to review the NDA for obeticholic acid in NASH has been postponed a second time, which means OCA likely will not be approved by 26 June.

Drug Approval Standards Advisory Committees

RESOLVE-IT Failure Dashes Genfit's NASH Hopes

Genfit SA is now pinning its hopes for elafibranor on primary biliary cholangitis after the dual PPAR alpha/delta agonist failed in its Phase III RESOLVE-IT trial for NASH.

Clinical Trials Companies

Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.

Clinical Trials Business Strategies

Payer KOL Says Expect “Levers” To Limit Early Uptake Of NASH Drugs

Liver health key opinion leaders say pre-authorization, requirements for biopsies or sicker patients could limit early uptake of NASH drugs. Intercept’s OCA, Genfit’s elafibranor both seen as likely combo therapy components.

Business Strategies Private Payers
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Hepatic (Liver)
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Genfit SA
  • Senior Management
  • Jean-Francois Mouney, Chmn. & CEO
    Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
    Dean Hum, PhD, COO
    Carol L Addy, MD, CMO
  • Contact Info
  • Genfit SA
    Phone: (33) 3 20 16 40 00
    885 Ave. Eugene Avinee
    Parc Eurasante
    Loos, 59120
    France
UsernamePublicRestriction

Register